Cell and Gene Therapy
🇪🇺 EMAEMA news and analysis for pharmaceutical BD, investment, and market access
Articles about Cell and Gene Therapy
Showing 1–8 of 8 articles
Quick answer
NovaPharmaNews Cell and Gene Therapy hub for EMA covers 8 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight — regulatory updates
ISCT 2026: EU Manufacturing Innovations Day 1 Roundup
EU Biopharma Clinical Trials: AI & Gene Therapy Surge
EMA Cell Therapy Framework: Impact on CAR-T Availability in Europe
ISCT 2026: Cell & Gene Therapy Manufacturing Innovations in Dublin
CAR-T Therapies Cost-Effectiveness: EU HTA Bodies' Divergent Assessments
EMA Conditional Approval CAR-T Therapy for Relapsed B-Cell Lymphoma
CHMP Positive Opinion CAR-T Therapy: What You Need to Know
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.